Clarification on the collaborative publication by OBI Pharma Inc. and Academia Sinica

OBI Pharma Inc. to attend The 37th Annual J.P. Morgan Healthcare Conference
January 3, 2019
Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study by Ministry of Health of Ukraine
February 20, 2019
  1. Date of occurrence of the event: Feb 13, 2019
  2. Company name: OBI Pharma Inc.
  3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office
  4. Reciprocal shareholding ratios: N/A
  5. Name of mass media: Page C5 of Economy Daily News on Feb 13, 2019
  6. Content reported: News article by Economy Daily News regarding the collaborative publication by OBI Pharma Inc. and Academia Sinica
  7. Cause of occurrence: Clarification on news article
  8. Countermeasures: Information regarding the press release has been made available to the public on Feb 12, 2019. For more detail, please visit OBI’s corporate website at http://www.obipharma.com. Publication related information can be found on PNAS’s official website at https://www.pnas.org/content/early/2019/02/08/1816946116.
  9. Any other matters that need to be specified: New drug development is a long process associated with high costs. It is not a guaranteed success, which may increase the risk of investment. Investors shall make prudent judgments and investments.